Latest news with #HIPEC
Daily Mirror
19 hours ago
- Health
- Daily Mirror
'I had 13 organs removed after I got food poisoning on a work night out'
A woman who struggled to recover from a bout of food poisoning after her Christmas work do went on to be diagnosed with a rare, incurable disease that killed a Hollywood actress It was Christmas 2018 when Rebecca Hind was struck down with a bout of nasty food poisoning at her work meal. She wasn't the only one to get it but while her colleagues recovered, two months on Rebecca was still suffering with sickness. She went to her doctor, who prescribed courses of antibiotics but she still didn't recover. Rebecca, from Eden Valley, Cumbria recalled: "After our Christmas 2018 work meal, a few of us were unwell - but whilst others recovered quickly, I remained ill eight weeks later. The GP had given me several rounds of antibiotics but nothing worked." She was referred to Cumberland Infirmary, Carlisle for a CT scan which showed she had masses in her abdomen. Biopsies followed which revealed the worst possible news - Rebecca, who was then 35, had cancer. The disease had fused to the surface of several of her abdominal organs and formed tumours which were preventing them from working properly. The type of cancer Rebecca was found to have was Pseudomyxoma peritonei (PMP) - the same cancer that killed movie star Audrey Hepburn. It's incredibly rare - just one to four in a million people per year are diagnosed with it. Rebecca was told it had spread to her organs via a jelly-like cancerous liquid called mucin and that it was advanced. "By the time they found it, I was pretty much riddled with it," she revealed. The former outdoor education instructor had noticed she was gaining weight unusually around her middle during that year but being a fan of keeping fit, she just exercised more to try and shift it. It turned out that her bigger tummy was the 'jelly-belly' that is characteristic of PMP and the mucin associated with it. Rebecca underwent surgery in April 2019 at the Christie Hospital in Manchester. Surgeons removed her appendix, navel, lesser omentum - a layer of tissue attached to the stomach and liver - and six litres of mucin. Tests showed that the cancer was a very aggressive form so she was given eight rounds of chemotherapy, but sadly the cancer didn't shrink enough. In November 2019 she underwent another lengthy operation in an attempt to remove all the diseased tissue. During the 12-hour surgery Rebecca had her greater omentum, gall bladder, spleen, large bowel, womb, uterus, ovaries, fallopian tubes, cervix, and rectum removed. She also had some of her stomach and small bowel taken away, as well as the surface layer of her liver and both sides of her diaphragm. Chemo was also given during the procedure. "I went through a surgical menopause aged 35 - it was an assault on the body," she recalled. "Part of the surgery I had a heated liquid form of chemotherapy - known as HIPEC - to target any remaining cancer cells and they formed an ileostomy [an opening in the belly]. I was in hospital recovering on and off for months after." Despite the best efforts of surgeons and specialists and the huge amount of organs and tissue that was removed, Rebecca was told the cancer was still present. She participated in a trial which targeted the genetic mutation associated with the disease in 2022, but the treatment made her too unwell. Tragically she was then told the cancer was incurable. "They surgically removed some diseased organs, and administered eight rounds of chemotherapy, but some disease remained. Then I had a second surgery so I was dealing with the life-changing effects of the surgery, and then I learned the cancer had returned and was incurable. It was heartbreaking," she said. She now takes 50 to 60 tablets a day including codeine and hormone replacement therapy. Her diet is restricted to an electrolyte fluid solution and food supplements. Despite the tragic prognosis, Rebecca, who turns 40 this year, remains positive and determined to live her life to the full - even though she doesn't know how long she has left. "I've just got to try to get on with life, and deal with whatever comes my way," she said. She's certainly keeping to her word too. So far she's had a go at surfing, enjoyed a hot air balloon ride and tried her hand at dog sledding. She is also raising money for a charity close to her heart. Her latest challenge is Chris Hoy's 'Tour de 4' 90km cycle. She's hoping to raise money for PMP charity Pseudomyxoma Survivor, which Audrey Hepburn's son is patron of. Rebecca believes a positive mindset is crucial to making the most of any situation and hopes to inspire others with her story. "The message I want to get across is when you have a stoma or an incurable diagnosis, things will be incredibly difficult," she said. "My daily life is a rollercoaster - but with the right attitude, you can still achieve a lot. And more importantly, enjoy whatever time you have." If you'd like to contribute to Rebecca's gofundme fundraiser you can do so here. What is PMP? Pseudomyxoma peritonei (PMP) is a very rare type of cancer, It usually starts in the appendix as a polyp but can also start in the bowel, bladder or ovaries. The polyp then spreads cancerous cells from the point of origin to the abdominal cavity lining - the peritoneum. The cells produce mucus called mucin which collects in the tummy. It's a jelly-like substance, hence PMP sometimes being called 'jelly belly'. The disease develops very slowly and it can take years for symptoms to show. It will usually have spread beyond the appendix once it is diagnosed. It can press on the bowel and other organs. Without treatment it can take over the peritoneal cavity. It's not known what causes the illness. It's more common in women and can be mistaken for ovarian cancer, which can also produce mucin and swelling in the tummy. Symptoms of PMP can include: abdominal or pelvic pain not being able to become pregnant abdominal swelling and bloating changes in bowel habits hernia (a bulge in the tummy wall or groin) loss of appetite feeling of fullness Diagnosis can be tricky and it's often discovered accidentally while treating another condition. A doctor will arrange for certain tests to be carried out before treatment, including an ultrasound, CT scan and MRI. Surgery and chemotherapy are the main treatments for PMP.
The Wire
2 days ago
- Health
- The Wire
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
KOLKATA, India, July 28, 2025 /PRNewswire/ -- In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites. When she came to Manipal Hospital Dhakuria, she had trouble breathing and was admitted to the ICU. In the ICU, the fluid in her lungs was drained and chemotherapy was done. Initially, she needed chemotherapy every week but as soon as her condition improvised, she needed it once in three weeks. Subsequently, she was also shifted to the general ward. "We are proud to announce the successful completion of our first CRS with HIPEC at Manipal Hospital Dhakuria—an emerging center for comprehensive cancer care in Kolkata," said Dr. Ashutosh Daga. He went on to add, "Although we have previously performed a lot of CRS procedures and managed numerous advanced malignancies in collaboration with our medical oncologists, this was our first CRS case incorporating HIPEC that paves the way for complex procedures at the hospital for cancer patients." Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a highly specialized and evolving treatment modality used in the management of select gynecological, gastrointestinal, and occasionally thoracic malignancies. This complex procedure demands surgical precision and seamless coordination across multiple departments—including Anesthesiology, Critical Care, Physical Medicine, and Transfusion Medicine. Dr. Sagnik Ray said, "After 5 months of chemotherapy, she underwent optimal cytoreduction followed by intraoperative delivery of heated chemotherapy using a dedicated HIPEC machine, and she responded to the treatment in a positive manner. The patient had an excellent recovery and was discharged in stable condition on the 9th day of the surgery." About Manipal Hospitals As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500 beds, a talented pool of 5,600 doctors and an employee strength of over 18,600. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys. (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.). PTI
Business Standard
2 days ago
- Health
- Business Standard
Successful Completion of First CRS with HIPEC on a 60-year-old Woman with Advanced Peritoneal Carcinomatosis
PRNewswire Kolkata (West Bengal) [India], July 28: In a landmark achievement, a 60-year-old woman with advanced primary peritoneal carcinomatosis was successfully treated with Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Manipal Hospital Dhakuria, under the expertise of Dr. Ashutosh Daga, Medical Oncologist, and Dr. Sagnik Ray, Surgical Oncologist. The 12-hour long procedure adds a milestone in cancer care treatment. The sexagenarian was initially taken to another hospital where she was misdiagnosed as a case of chronic liver failure with ascites. When she came to Manipal Hospital Dhakuria, she had trouble breathing and was admitted to the ICU. In the ICU, the fluid in her lungs was drained and chemotherapy was done. Initially, she needed chemotherapy every week but as soon as her condition improvised, she needed it once in three weeks. Subsequently, she was also shifted to the general ward. "We are proud to announce the successful completion of our first CRS with HIPEC at Manipal Hospital Dhakuria--an emerging center for comprehensive cancer care in Kolkata," saidDr. Ashutosh Daga. He went on to add, "Although we have previously performed a lot of CRS procedures and managed numerous advanced malignancies in collaboration with our medical oncologists, this was our first CRS case incorporating HIPEC that paves the way for complex procedures at the hospital for cancer patients." Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a highly specialized and evolving treatment modality used in the management of select gynecological, gastrointestinal, and occasionally thoracic malignancies. This complex procedure demands surgical precision and seamless coordination across multiple departments--including Anesthesiology, Critical Care, Physical Medicine, and Transfusion Medicine. Dr. Sagnik Ray said, "After 5 months of chemotherapy, she underwent optimal cytoreduction followed by intraoperative delivery of heated chemotherapy using a dedicated HIPEC machine, and she responded to the treatment in a positive manner. The patient had an excellent recovery and was discharged in stable condition on the 9th day of the surgery." About Manipal Hospitals As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 37 hospitals across 19 cities with 10,500+ beds, a talented pool of 5,600+ doctors and an employee strength of over 18,600. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.
Mint
14-07-2025
- Health
- Mint
Oncologist shares 10 key facts about neuroendocrine tumours you should know
When we think about cancer, common types like breast, lung, or colon cancer often come to mind. However, Neuroendocrine Tumours (NETs) deserve attention too. Usually overshadowed by more prevalent cancers, NETs are becoming increasingly common, according to the scientific journal Springer. They are frequently diagnosed late due to their vague symptoms, which can be easily mistaken for other health issues. Here are 10 facts about neuroendocrine tumours that everyone should be aware of. Dr Vinay Samuel Gaikwad, Head & Director – Surgical Oncology at Fortis Hospital, emphasises that understanding the nuances of neuroendocrine tumours is crucial for improving patient outcomes and treatment efficacy. Neuroendocrine tumours arise from neuroendocrine cells, which are unique cells that are found throughout the body, particularly in the stomach, intestines, pancreas, and lungs. These cells produce hormones that regulate various functions. When they begin to grow abnormally, they can form tumours, some of which can be slow-growing. In contrast, others may be aggressive, as seen in the Institute for Quality and Efficiency in Health Care (IQWiG). One of the biggest hurdles with NETs is that they often remain asymptomatic until advanced stages, as per StatPearls. Common symptoms include: Abdominal pain Diarrhea Sweating Unexpected weight loss Weakness Skin flushing These symptoms could easily be mistaken for everyday problems like stress or irritable bowel syndrome, potentially leading to misdiagnosis or delayed treatment. Many individuals with NETs are diagnosed at later stages due to unclear symptoms. Often, these tumours are identified incidentally during imaging tests done for unrelated conditions. Unfortunately, by that time, the cancer may have already spread, complicating treatment as per Worldwide Cancer Research. The rising neuroendocrine tumour cases can be linked to two key factors: Advanced screening: Improved diagnostic techniques are enabling healthcare providers to identify NETs more frequently. Improved diagnostic techniques are enabling healthcare providers to identify NETs more frequently. Lifestyle and environmental factors: Changes in lifestyle and environmental exposures are likely contributing to this increase. Treatment for NETs depends on various aspects, including: The location of the tumour Its aggressiveness Whether it has metastasised (spread) Surgery: Early detection often allows for successful surgical removal. Early detection often allows for successful surgical removal. Minimally invasive techniques: Laparoscopic and robotic surgeries can reduce recovery time and complications. Laparoscopic and robotic surgeries can reduce recovery time and complications. Medical treatments: For advanced tumours, treatment may involve targeted medications, hormone therapies, or radiation. For advanced tumours, treatment may involve targeted medications, hormone therapies, or radiation. Specialised procedures: Techniques such as HIPEC (Hyperthermic Intraperitoneal Chemotherapy) may be utilised in specific situations. Raising awareness is crucial. Both the public and healthcare professionals need to recognise the signs of NETs early, as catching them in time can lead to significantly better outcomes, according to Dr Vinay, an oncologist. While the definitive causes of NETs are unclear, certain risk factors can heighten one's risk of developing these tumours: Family history of neuroendocrine cancers Genetic syndromes, such as Multiple Endocrine Neoplasia (MEN) Age, as risk increases with age Managing life with a neuroendocrine tumour presents challenges, as per the journal Oncology and Therapy. Patients are encouraged to: Stay educated about their condition Maintain open communication with healthcare professionals Join support groups for emotional and psychological support Lifestyle choices matter. A balanced diet, regular exercise, and effective stress management techniques can enhance overall health and support the management of neuroendocrine tumours, as per The Nutrition Source. Promoting awareness about NETs is vital. The more knowledge shared regarding these tumours, the better chances patients have of recognising symptoms early. Advocacy, education, and community outreach can significantly enhance understanding and promote essential testing. Neuroendocrine tumours may not be the most recognised kinds of cancer, but understanding them is key for early detection and treatment response. If you or someone you know experiences unusual symptoms like chronic stomach issues or sudden weight loss, it may be time to advocate for further testing.
Medscape
07-07-2025
- Health
- Medscape
Paclitaxel Matches Cisplatin HIPEC in Ovarian Cancer
TOPLINE: Patients with advanced ovarian cancer undergoing interval cytoreductive surgery who received paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) during surgery appeared to have comparable overall survival and disease-free survival rates to those who received cisplatin-based HIPEC. METHODOLOGY: Although the use of HIPEC remains controversial, cisplatin-based HIPEC during cytoreductive surgery may benefit patients with advanced ovarian cancer; however, there is less evidence for paclitaxel-based HIPEC, typically used in patients who are frail or intolerant to platinum agents. To compare the two regimens, researchers analyzed data from the National Registry of Peritoneal Carcinomatosis, which included 846 patients (mean age, 59 years) who underwent interval cytoreductive surgery with either cisplatin-based HIPEC (n = 325) or paclitaxel-based HIPEC (n = 521). After propensity score matching, there were 199 patients per group (total = 398). HIPEC was administered post-surgery with cisplatin (75-100 mg/m2 for 90 minutes) or paclitaxel (120 mg/m2 for 60 minutes), both at 42-43 °C. TAKEAWAY: Using cisplatin as the reference group, the median overall survival was not significantly different between the two options (hazard ratio [HR], 0.74; P = .16); however, the median overall survival was 82 months in the paclitaxel group vs 58 months in the cisplatin group. Disease-free survival was also not significantly different between the two groups, with a median of 20 months in the cisplatin group and 21 months in the paclitaxel groups (HR, 0.95; 95% CI, 0.72-1.25; P = .70). Overall survival was comparable during the first 20 months of follow-up and disease-free survival was equivalent during the first 15 months of follow-up, based on a predefined equivalence margin of 0.1. Paclitaxel-based HIPEC was not associated with increased morbidity (odds ratio, 1.32; P = .06). IN PRACTICE: 'Our study suggests that cisplatin and paclitaxel are two safe and effective drugs to be used for HIPEC in [interval cytoreductive surgery] for advanced ovarian cancer. As cisplatin is the preferred drug according to strong evidence, paclitaxel could be a valuable alternative for patients with any contraindication to cisplatin, with similar oncological and perioperative outcomes,' the authors wrote. SOURCE: This study, led by Salud González Sánchez, MD, Reina Sofía University Hospital in Córdoba, Spain, was published online in JAMA Network Open. LIMITATIONS: The retrospective design of this study limited causal inference. The BRCA mutation status was not captured in the national registry. Additionally, the matching procedure resulted in a moderate sample size, which could have led to residual confounding. DISCLOSURES: The authors did not declare any funding information and reported no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
